KalVista Pharmaceuticals Income Statement (2014-2025) | KALV

1Y3Y5Y7Y10YAll
Download Data
Income Statement Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jul2016 Oct2016 Jan2017 Apr2017 Jul2017 Oct2017 Jan2018 Apr2018 Jul2018 Oct2018 Jan2019 Apr2019 Jul2019 Oct2019 Jan2020 Apr2020 Jul2020 Oct2020 Jan2021 Jul2023 Oct2023 Jan2024 Apr2024 Jul2024 Oct2024 Apr2025
Revenue & cost
Revenue 0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.01M0.97M0.20M0.25M0.11M0.10M1.13M2.33M4.84M3.72M5.59M3.89M2.93M3.37M3.92M1.58M3.82M
Operating items
Research & Development 1.43M1.75M2.09M3.90M4.50M3.53M4.26M3.53M3.40M2.93M3.34M3.00M3.48M4.36M4.55M5.85M8.36M7.88M7.65M11.14M9.69M9.79M11.23M9.48M22.52M25.25M26.61M15.89M
Selling, General & Administrative 0.44M0.69M1.49M1.01M1.17M1.37M1.32M1.54M2.70M1.29M5.03M2.20M2.07M2.70M2.13M1.96M2.37M2.61M2.90M3.05M3.25M3.42M3.07M3.30M10.63M23.21M17.60M39.14M
Other Operating Expenses 3.83M-0.00M1.46M0.00M-9.56M
Operating Expenses 1.86M2.44M3.58M3.83M4.91M5.67M4.91M5.58M6.54M6.09M4.22M8.37M5.20M5.55M7.06M6.68M7.81M10.73M10.48M10.55M14.19M12.93M13.21M14.30M12.78M33.15M48.45M44.22M55.03M
Operating Income -1.86M-2.44M-3.57M-4.90M-5.67M-4.90M-5.57M-6.53M-5.12M-4.03M-8.12M-5.09M-5.45M-5.94M-4.35M-2.97M-7.01M-4.89M-6.66M-11.26M-9.56M-9.29M-12.72M-8.96M-33.15M-48.45M-44.22M-55.03M
EBIT -1.86M-2.44M-3.57M-4.90M-5.67M-4.90M-5.57M-6.53M-5.12M-4.03M-8.12M-5.09M-5.45M-5.94M-4.35M-2.97M-7.01M-4.89M-6.66M-11.26M-9.56M-9.29M-12.72M-8.96M-33.15M-48.45M-44.22M-55.03M
Non-operating items
Interest & Investment Income -0.08M0.00M0.00M0.55M0.00M0.00M0.00M0.01M0.01M0.01M0.01M0.01M0.00M0.00M0.01M0.07M0.09M0.20M0.72M0.38M0.59M0.51M0.37M0.36M0.68M1.51M1.69M1.99M
Other Non Operating Income -0.12M-0.07M0.55M-3.18M0.00M-0.00M1.39M0.37M0.66M0.82M0.56M0.87M-1.89M1.99M1.82M1.62M1.73M2.51M2.09M2.32M2.92M2.50M2.32M2.43M1.57M0.02M
Non Operating Income -0.16M-0.20M-0.07M0.55M-0.00M0.00M-4.36M-0.00M1.68M0.73M0.66M0.88M0.56M0.95M0.98M1.99M1.98M1.62M2.70M2.86M2.23M3.39M3.43M2.25M4.12M3.81M3.77M1.95M
Net income details
EBT -2.02M-2.52M-3.92M-5.18M-5.83M-4.99M-5.66M-6.60M-5.11M-4.01M-8.11M-5.08M-5.45M-5.94M-4.33M-2.90M-6.92M-4.69M-5.94M-10.88M-8.97M-8.78M-12.35M-8.59M-29.03M-44.65M-40.44M-53.08M
Tax Provisions -0.85M
Profit After Tax -2.02M-2.63M-4.00M-4.71M-5.18M-9.01M-4.99M-5.66M-6.61M-3.44M-3.30M-7.64M-4.20M-4.93M-4.99M-5.23M-0.66M-5.03M-3.30M-3.96M-8.53M-7.34M-5.90M-9.29M-6.58M-29.03M-44.65M-40.44M-52.23M
Income from Continuing Operations -2.02M-2.52M-3.92M-5.18M-5.83M-4.99M-5.66M-6.60M-5.11M-4.01M-8.11M-5.08M-5.45M-5.94M-4.33M-2.90M-6.92M-4.69M-5.94M-10.88M-8.97M-8.78M-12.35M-8.59M-29.03M-44.65M-40.44M-52.23M
Consolidated Net Income -2.02M-2.52M-3.92M-5.18M-5.83M-4.99M-5.66M-6.60M-5.11M-4.01M-8.11M-5.08M-5.45M-5.94M-4.33M-2.90M-6.92M-4.69M-5.94M-10.88M-8.97M-8.78M-12.35M-8.59M-29.03M-44.65M-40.44M-52.23M
Income towards Parent Company -2.02M-2.52M-3.92M-5.18M-5.83M-4.99M-5.66M-6.60M-5.11M-4.01M-8.11M-5.08M-5.45M-5.94M-4.33M-2.90M-6.92M-4.69M-5.94M-10.88M-8.97M-8.78M-12.35M-8.59M-29.03M-44.65M-40.44M-52.23M
Net Income towards Common Stockholders -2.02M-2.52M-3.92M-5.18M-5.83M-4.99M-5.66M-6.60M-4.47M-4.24M-7.86M-4.20M-4.93M-4.99M-5.23M-0.66M-6.92M-4.69M-5.94M-10.88M-8.97M-8.78M-12.35M-8.59M-29.03M-44.65M-40.44M-52.23M
Additional items
EPS (Basic) -4.39-4.26-5.89-6.82-7.38-0.40-0.19-0.30-0.25-6.66-5.98-1.03-0.90-0.51-0.50-0.49-0.06-0.47-0.22-0.23-0.72-0.42-0.33-0.52-0.48-0.84-1.07-0.87-0.99
EPS (Weighted Average and Diluted) -0.48-0.84-1.07-0.87-0.99
Shares Outstanding (Weighted Average) 0.46M0.62M0.68M0.61M0.70M22.62M26.32M19.08M26.33M0.67M0.71M7.66M4.65M9.71M10.00M10.79M10.32M10.80M15.11M17.23M15.08M17.49M17.82M17.84M17.75M17.85M17.91M17.96M34.41M34.57M34.72M36.79M46.23M46.70M
Shares Outstanding (Diluted Average) 17.75M34.41M34.57M34.72M36.79M46.23M46.70M
EBITDA -1.86M-2.44M-3.57M-4.90M-5.67M-4.90M-5.57M-6.53M0.89M-1.97M-7.48M-3.94M-4.81M-5.03M-2.80M-1.63M-6.35M-3.11M-3.82M-8.35M-7.40M-5.38M-9.21M-7.08M-28.86M-44.84M-39.82M-55.23M
Interest Expenses 0.08M0.08M0.36M0.56M0.84M0.17M0.10M0.09M0.09M
Tax Rate 1.60%